Sarah Carmody | IR and Corporate Communications |
Anna Protopapas | CEO |
Tim Lowinger | Chief Scientific Officer |
Dave Spellman | CFO |
Eva Jack | Chief Business Officer |
Dirk Huebner | CMO |
Jonathan Chang | SVB Leerink |
Mike Ulz | Robert W. Baird |
Jessica Fye | JP Morgan |
David Nierengarten | Wedbush Securities |
Debjit Chattopadhyay | H.C. Wainwright |
Good morning and welcome to Mersana Therapeutics’ Fourth Quarter and Full Year 2018 Conference Call. Currently, all participants are in listen-only mode. There will be a question-and-answer session at the end of this call. I would now like to turn the call over to Sarah Carmody, Director, Investor Relations and Corporate Communications. Please proceed.